Dr Burke on the Influence of the SHINE and TRIANGLE Trials on Ibrutinib Use in MCL

John M. Burke, MD, discusses the influence of two key BTK inhibitor combination studies on therapeutic approaches for patients with previously untreated mantle cell lymphoma.

Related Keywords

Johnm Burke , ,Mountain Cancer Centers ,Hematology Research Program ,Rocky Mountain Cancer Centers ,Onclive Tv ,Mantle Cell Lymphoma ,Shine ,Triangle ,Ibrutinib ,